Ownership and insider activity for 10x Genomics, Inc. (TXG): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
Price
| Price | $97.74 |
| Market Cap | $12.4B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-22 | SULIMAN SHEHNAAZ | S-Sale | 292 | $23K |
| 2026-09-22 | SULIMAN SHEHNAAZ | S-Sale | 614 | $49K |
| 2026-09-22 | SULIMAN SHEHNAAZ | S-Sale | 1,325 | $107K |
| 2026-09-22 | SULIMAN SHEHNAAZ | S-Sale | 2,270 | $185K |
| 2026-09-22 | SULIMAN SHEHNAAZ | S-Sale | 1,222 | $101K |
| 2026-09-22 | Saxonov Serge | S-Sale | 1,000 | $78K |
| 2026-09-22 | Saxonov Serge | S-Sale | 2,000 | $159K |
| 2026-09-22 | Saxonov Serge | S-Sale | 9,300 | $752K |
| 2026-09-22 | Saxonov Serge | S-Sale | 9,900 | $810K |
| 2026-09-22 | Saxonov Serge | S-Sale | 2,800 | $231K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.9M | $65.1M | $424.2M | $663.6M | $587.4M | $219.7M | $359.3M | $344.1M | $474.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $210.2M | $29.4M | $49.3M | $49.4M |
| Receivables | $13.3M | $28.1M | $33.4M | $51.2M | $85.3M | $104.2M | $114.8M | $87.9M | $82.5M |
| Inventory | $4.8M | $8.6M | $15.3M | $30.0M | $60.0M | $81.6M | $73.7M | $83.1M | $56.3M |
| Total Current Assets | $68.1M | $106.2M | $480.8M | $774.4M | $747.6M | $635.0M | $596.0M | $584.4M | $684.5M |
| Property, Plant & Equipment | $6.9M | $11.1M | $48.8M | $119.8M | $230.4M | $359.2M | $344.9M | $309.9M | $287.2M |
| Goodwill | 0 | 0 | 0 | 0 | $4.5M | $4.5M | $4.5M | $4.5M | $4.5M |
| Intangible Assets | 0 | 0 | $22.4M | $22.4M | $25.4M | $22.9M | $16.6M | $15.7M | $62.3M |
| Total Assets | $75.6M | $124.3M | $605.9M | $929.3M | $1.02B | $1.03B | $965.1M | $918.6M | $1.04B |
| Accounts Payable | $5.4M | $8.8M | $13.0M | $4.7M | $17.4M | $21.6M | $15.7M | $12.9M | $12.7M |
| Short-term Debt | $4.2M | $4.2M | $9.9M | 0 | 0 | 0 | 0 | 0 | $11.0M |
| Total Current Liabilities | $22.1M | $32.4M | $63.0M | $118.1M | $110.4M | $131.0M | $127.2M | $117.6M | $153.5M |
| Long-term Debt | $6.3M | $25.5M | $19.8M | 0 | 0 | 0 | 0 | 0 | $73.4M |
| Total Liabilities | $188.1M | $344.3M | $185.8M | $190.3M | $201.3M | $223.2M | $224.1M | $208.5M | $245.0M |
| Retained Earnings | -$118.6M | -$231.1M | -$262.4M | -$805.1M | -$863.3M | -$1.03B | -$1.28B | -$1.47B | -$1.51B |
| Total Equity | -$112.5M | -$220.0M | $420.1M | $739.1M | $817.6M | $805.7M | $741.0M | $710.1M | $796.3M |
| Total Debt | $10.6M | $29.7M | $29.7M | $63.0M | $82.0M | $95.2M | $95.4M | $82.6M | $157.7M |
| Net Debt | -$37.3M | -$35.4M | -$394.4M | -$600.6M | -$505.5M | -$334.8M | -$293.3M | -$310.8M | -$365.7M |
| Working Capital | $46.0M | $73.9M | $417.8M | $656.2M | $637.2M | $504.1M | $468.9M | $466.8M | $531.0M |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 5.69 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.83 |
Profitability
| Return on Equity | -9.33% |
| Return on Invested Capital | -9.57% |
| Return on Assets | -7.29% |
| Gross Margin | 70.03% |
| Operating Margin | -14.33% |
| Net Margin | -12.18% |
Related companies: CERT · GRDN · JANX · NUVB · OMCL · OMDA · PGNY
Explore sector: Healthcare · Biotechnology
More sections of TXG: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks